Tenaya Therapeutics and Alnylam Pharmaceuticals have agreed to collaborate on identifying potential new gene therapies for the treatment of cardiovascular disease. Tenaya will receive an upfront payment of $10 million, but stands to earn much more.
Freestanding EDs demonstrated meaningful operational advantages over hospitals when using an accelerated troponin pathway. This included earlier discharges for low-risk chest pain patients.
The AI model showcased an ability to accurately identify signs of pulmonary hypertension in retinal images. "This opens the possibility of using a simple photograph to gain insights into a premature infant's overall health," one researcher explained.
The AI-powered Relief System is able to modulate venous pressure using hemodynamic data. The goal is to help patients better manage heart failure congestion at home.
STS plans on using new research out of Mayo Clinic to help with the development of a surgical risk calculator for adults with this challenging condition.
Researchers examined the brains of bilingual and monolingual people using fMRI, only to find improved communication between isolated regions in those who learn a second language at a young age.
Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.
The popular AI chatbot tends to over-order X-rays, prescribe too many antibiotics and admit too many patients to the hospital when compared with a resident emergency department physician.
This study adds to growing evidence that e-cigarettes play a significant role in cardiovascular problems, similar to smoking. Researchers hope their work can help lead to new public health policies.
Millions of heart failure patients who qualify for standard medical therapies do not receive treatment due to poor health literacy, limited access to care and medication costs.
GE HealthCare's flurpiridaz, the PET radiotracer that recently received FDA approval, offers several key benefits over SPECT. Jamshid Maddahi, MD, discussed the details in an exclusive interview.
